LIXT News

Latest breaking news and updates for LIXT stock.

24/7 Market News: LIXTE Biotechnology Spotlight- Revisiting the “Too Much of a Good Thing” Strategy for LB-100

LIXTE’s (Nasdaq: LIXT) lead compound, LB 100, was featured in Nature Reviews Cancer editorial titled “Too Much of a Good Thing”

Clinical trials

4 days ago

Read more globenewswire

LIXTE Biotechnology Holdings Provides Corporate Update

-Completes Two Financings, Raising $6.5 Million-

Will the capital raise accelerate product milestones or impact upcoming catalysts for LIXT? What are the terms and valuation of the two financings compared to recent market comps? How will the $6.5 million financing affect LIXT's cash runway and dilution?

5 days ago

Read more globenewswire

24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with First Phase 1B/2 Trial Readout Expected in 2H 2025

2H 2025 is shaping up to be a defining year for LIXTE (Nasdaq: LIXT) and its lead compound LB-100

Are there any macro or sector‑wide factors that could amplify or dampen the stock’s response to the 2H 2025 trial readout? What historical price reaction has LIXTE exhibited to prior clinical trial announcements? How could the upcoming data release affect LIXTE’s trading volume and liquidity on Nasdaq?

Clinical trials

9 days ago

Read more globenewswire

24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with Multiple Phase 1B/2 Trial Readouts Expected in 2H 2025

2025 is shaping up to be a defining year for LIXTE (Nasdaq: LIXT) and its lead compound LB-100

How might macroeconomic conditions in 2025 affect the funding environment for biotech companies like LIXTE? What impact could a positive readout have on institutional ownership or short interest levels? How does the timing of LIXTE's readouts align with broader market or sector trends in precision oncology?

Clinical trials

9 days ago

Read more globenewswire

24/7 Market News: LIXTE Biotechnology Holdings Embraces Cryptocurrency in Corporate Treasury Strategy

LIXTE’s (Nasdaq:LIXT) BoD approved a bold new treasury policy to diversify its corporate reserves into cryptocurrency, including $BTC & potentially others

How might this decision affect LIXTE's relationships with existing shareholders who have a traditional risk‑averse outlook? Will this treasury policy impact LIXTE's R&D funding timeline or capital allocation for upcoming projects? What are the contingency plans if the cryptocurrency market experiences a significant downturn or liquidity crisis?

Finance

10 days ago

Read more globenewswire

LIXTE Biotechnology Holdings Updates Corporate Treasury Policy to Include Cryptocurrency

PASADENA, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announce...

Will the crypto holdings be used for any strategic purposes (e.g., funding collaborations, M&A, or liquidity needs) or remain purely as a reserve asset? How might macro‑crypto market dynamics (e.g., Bitcoin price swings, network upgrades, or market sentiment) impact LIXTE's overall financial performance? What safeguards, custody solutions, and insurance policies does LIXTE have in place to protect against theft or loss of digital assets?

10 days ago

Read more globenewswire